Aastrom Biosciences ends drug trial, to cut half its workforce

(Reuters) – Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia – a form of peripheral arterial disease – and cut about half of its workforce. The company now plans to focus on its experimental treatment for a heart condition called dilated cardiomyopathy, in which the heart becomes weak and cannot pump blood efficiently. The company has about 71 employees, according to Thomson Reuters data. (Reporting By Vrinda Manocha and Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)

Popularity helps buffer Apple from Chinese state-media attacks

People walk past the Apple logo near an Apple Store at a shopping area in central BeijingBy Melanie Lee SHANGHAI (Reuters) – Chinese Internet users are crying foul over the perceived unfair treatment doled out to Apple Inc by state-run media which has actively criticized the smartphone maker for the past two weeks over its warranty policy. Apple and Volkswagen AG were singled out on March 15 by state-run China Central Television in its annual corporate malpractice expose. CCTV accused Apple of having discriminatory after-sales service in China compared to the rest of the world. …

1 8 9 10 11 12 83